June 2026 · 11 min read · Clinical Operations
Understanding PEMF Treatment Parameters
PEMF (Pulsed Electromagnetic Field) devices generate time-varying magnetic fields that penetrate tissue to a depth of 20–25 cm — far beyond the 5 cm maximum of manual therapies and the 3–5 cm of therapeutic ultrasound. The clinical outcome depends on five independently adjustable parameters:
- Frequency (Hz): 1–100 Hz; most therapeutic applications use 3–75 Hz. Frequency determines which cellular targets are activated (see table below).
- Magnetic field intensity (mT): 1–100 mT; most clinical protocols use 2–20 mT. Higher is not always better — optimal intensity is indication-specific.
- Session duration: 20–40 minutes; sufficient for full ion cyclotron resonance cycle completion in target tissue.
- Pulse shape: sinusoidal, square, or triangular; affects energy delivery profile and tissue specificity.
- Coil configuration: flat applicator, saddle coil, or cylindrical — selected based on treatment area anatomy.
Frequency Protocols by Pathology
Frequency selection is the primary clinical decision. Decades of research and 70+ Israeli clinics (population: 9M) — now expanding to the Philippines — have produced frequency-to-indication mapping validated in RCTs:
| Frequency Range | Biological Target | Primary Indications |
|---|---|---|
| 1–5 Hz (delta range) | Osteoblast activation, peripheral nerve regeneration | Bone fracture non-union, peripheral neuropathy |
| 6–12 Hz (alpha range) | Adenosine-A2A activation, cortisol normalization, pain gating | Chronic pain, anxiety, insomnia, fibromyalgia |
| 10–25 Hz | Nociceptive threshold elevation, membrane stabilization | Radiculopathy, neuropathic pain, nerve root compression |
| 25–50 Hz | Cytokine suppression (IL-1β, TNF-α), microcirculation improvement | Osteoarthritis, rheumatoid arthritis, inflammatory conditions |
| 50–75 Hz | Muscle fiber relaxation, DOMS clearance, creatine kinase metabolism | Sports recovery, DOMS, myofascial pain |
| 75–100 Hz | Rapid pain signal gating, acute edema reduction | Acute injury, post-surgical swelling, acute exacerbations |
Standard PEMF Session Structure
Each PEMF session follows a four-stage workflow that allows one therapist to run multiple machines simultaneously — the operational model that drives the economics of PEMF clinics:
- Pre-session screen (5 min): contraindication checklist (pacemaker, pregnancy, epilepsy, malignancy in field), VAS/NRS pain score, brief functional assessment. First session adds 10–15 min for full medical history.
- Setup and positioning (5 min): patient seated or supine per protocol, coil positioned over target anatomy, device programmed for indication-specific frequency and duration.
- Active treatment (20–40 min): patient remains stationary; no therapist attendance required during this phase (the key operational efficiency driver).
- Post-session documentation (5 min): VAS re-score, note changes, update treatment plan. Total clinic time: 35–55 minutes per patient.
The unsupervised treatment phase means a single PEMF machine can be staggered to treat 8–10 patients per 8-hour clinic day — the capacity model that underlies the investor revenue projection.
Treatment Course Overview by Indication
| Indication | Sessions/Week | Total Course | Expected First Response | Evidence Source |
|---|---|---|---|---|
| Chronic low back pain | 2–3 | 10–20 sessions | Sessions 3–5 | PMC11914662 (n=91, 36% pain reduction) |
| Knee osteoarthritis | 3–5 | 20–30 sessions | 4–6 weeks | PMC9110240 (11 RCTs, n=614, SMD 1.52) |
| Fibromyalgia | 3 | 15–20 sessions | Sessions 6–8 | PMC9524818 (VAS −48 pts vs −17 placebo) |
| Diabetic neuropathy | 5 (or 2×/day) | 30–36 sessions (18 weeks) | Weeks 4–6 | PMC11874150 RELIEF Trial (n=182, 85% vs 25%) |
| Post-surgical recovery | 3–5 | 8–12 sessions | Week 1 (edema/pain) | PMID 28060214 (2.1x analgesic reduction) |
| Sports recovery (acute) | 5 | 5–10 sessions | Sessions 1–3 | PMC9325280 (RTP 9.4 vs 15.2 days) |
| Bone fracture non-union | 3 | 36–60 sessions (3–6 months) | Radiographic at 8–12 weeks | PMID 32495506 (14 RCTs, RR=1.22, 79.7% vs 64.3%) |
| Cervical radiculopathy | 3 | 12 sessions (4 weeks) | Sessions 3–5 | RCT n=34 (VAS SMD=−0.89 P<0.001) |
| Plantar fasciitis | 3–5 | 10–15 sessions | Sessions 2–4 | PMID 22297104 (RCT, n=70, 40% vs 7% morning pain); PMID 40378087 (case series, fascia thickness −34%) |
| Rheumatoid arthritis | 3 | 12–15 sessions | Sessions 4–6 | PMC10971695 (n=39, VAS −2.2 p=0.0000) |
| Anxiety / GAD | 3 | 12–15 sessions | Sessions 4–6 | PMC9748435 (HAMA 40% vs 14%, cortisol −28%) |
| Insomnia | 3 | 12 sessions | Sessions 3–5 | PMC7569862 (PSQI 14.2→8.1, onset −22 min) |
Important context on these figures. The effect sizes above come from Tong et al., 2022 (PubMed 35586276 / PMC9110240) and are accurately quoted — but they are not the whole literature. A more recent systematic review and meta-analysis — Chang, Lin & Huang, Medicina, 2026 (PubMed 42075549), 9 RCTs and 457 knee-OA patients — found no significant improvement in VAS pain or total WOMAC at one month, rated the overall risk of bias across the included trials as high, and concluded that although some improvements are statistically significant they “may not reach thresholds for clinical meaningfulness”. Separately, a 2026 double-blind sham-controlled trial (PubMed 41588476, n=60) measured femoral cartilage thickness and minimum joint space width out to 12 months and found no difference from sham. PEMF relieves symptoms; it does not rebuild the joint. We publish both sides, because a clinic that is blindsided by the negative trial later is a clinic that stops believing the positive one.
What Patients Experience: Session-by-Session Guide
Managing patient expectations is critical to treatment completion and clinic retention. Clinic staff should communicate this timeline during onboarding:
- Sessions 1–3: mild warmth or tingling during treatment (normal electromagnetic sensations). Subjective pain relief is often not yet perceived. Tissue changes are occurring at the cellular level — below conscious threshold.
- Sessions 4–6: typical first subjective improvement — reduced morning stiffness, easier range of motion, lower analgesic use. Patients who report "nothing happening yet" most commonly experience their first noticeable shift in this window.
- Sessions 7–12: measurable VAS/functional score improvement. The 36% pain reduction reported in PMC11914662 was measured at this stage. Medication reduction typically begins here.
- Beyond session 12: progressive consolidation. Chronic pain patients (fibromyalgia, OA, neuropathy) continue improving through sessions 15–25 as neuroinflammation resolves and neuroplastic remodeling progresses.
- Acute injury patients: may respond within 1–3 sessions — post-surgical swelling reduction and DOMS clearance are often visible at session 1–2.
Combination Protocol Architecture
PEMF delivers its highest outcomes when sequenced correctly within a multi-modal treatment session:
- PEMF before manual therapy: 20-minute PEMF session reduces tissue hypertonicity and cytokine load, enabling deeper and safer joint mobilization. This sequence is used in the majority of 70+ Israeli clinics (population: 9M) — now expanding to the Philippines.
- PEMF before therapeutic exercise: pain threshold lowered by PEMF allows patients to engage with exercise regimes they previously could not tolerate — improving compliance and functional outcomes.
- PEMF + acupuncture (sequential): PEMF first activates adenosine-A2A pathways; acupuncture 5 minutes later targets the same points via a different mechanism. Particularly effective for chronic pain with myofascial component.
- PEMF + ultrasound (sequential): PEMF addresses deep tissue and nerve; ultrasound targets superficial soft tissue. Combined for tendinopathy and post-surgical scar tissue.
Patient Selection: Who Is an Ideal Candidate?
PEMF has exceptionally broad eligibility — broader than any other electrophysical modality:
- Ideal candidates: patients who have failed or partially responded to NSAIDs, physiotherapy, or injections; patients seeking drug-free alternatives; post-surgical patients from day 1; athletes in active recovery
- Age range: no lower or upper age limit; pediatric and geriatric patients are both eligible
- Comorbidities: diabetes, cardiovascular disease, autoimmune conditions — all compatible; diabetic patients particularly benefit (DPN, wound healing)
- Metallic implants: generally compatible (orthopedic hardware, dental implants) — verify against specific device specifications
Absolute Contraindications
PEMF's contraindication list is narrow, affecting <3% of the typical clinic population:
- Active implanted electronic device (pacemaker, cochlear implant, intrathecal pump)
- Pregnancy (precautionary; no adverse outcomes reported, but insufficient safety data)
- Active uncontrolled epilepsy
- Active malignancy in the direct treatment field
Clinic Revenue Model
Understanding treatment course economics is essential for PEMF clinic viability planning. Based on the indication mix and treatment course data above:
- Session pricing: ₱1,500–₱2,500/session (Philippine market, mid-tier positioning)
- Average course revenue per patient: ₱15,000 (10 sessions, acute) to ₱75,000 (30 sessions, OA/neuropathy)
- Machine daily capacity: 8–10 patients/day (staggered scheduling; unsupervised treatment phase enables this throughput)
- Machine ROI timeline: 8–18 months at moderate patient volume (varies by local market pricing and lease costs)
- Recurring revenue: OA, neuropathy, and chronic pain patients return for maintenance sessions — typically monthly or quarterly after initial course completion
Request the complete investor brief including machine specifications, full revenue model projections, and Philippine market sizing data.
Request Investment Brief →